Multiepitope Peptide Vaccination in Melanoma

Charite University, Berlin, Germany25 enrolled

Overview

This trial assesses the clinical efficacy of a multiepitope peptide vaccine with GM-CSF and KLH as immunological adjuvants in stage IV melanoma patients

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Metastatic Melanoma

Interventions

Tyrosinase, MAGE-3, GnTVBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Metastatic melanoma * HLA-A1, -A2, -A24, -B44 Exclusion Criteria:

Locations (1)

Hem&Onc Charité CBF

Berlin, Germany

Outcomes

Primary Outcomes

Clinical efficacy

Secondary Outcomes

Immune response

Safety

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.